Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
作者信息
Lee Sung Hwan, Yim Sun Young, Kim Ji Hoon, Lee Sunyoung S, Kaseb Ahmed O, Wei Peng, Lee Ju-Seog
机构信息
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
Abstract
摘要
相似文献
1
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
2
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
3
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
4
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
5
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
6
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
7
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
8
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].
Clin Mol Hepatol. 2025 Apr;31(2):669-670. doi: 10.3350/cmh.2024.0333e. Epub 2025 Feb 27.
9
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
10
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
本文引用的文献
1
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.
Clin Mol Hepatol. 2025 Jan;31(1):e31-e34. doi: 10.3350/cmh.2024.0628. Epub 2024 Sep 20.
2
Emerging methods and techniques for cancer biomarker discovery.
Pathol Res Pract. 2024 Oct;262:155567. doi: 10.1016/j.prp.2024.155567. Epub 2024 Aug 29.
3
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
4
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.
7
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.
8
The cancer biomarker problem.
Nature. 2008 Apr 3;452(7187):548-52. doi: 10.1038/nature06913.
9
Evaluating the yield of medical tests.
JAMA. 1982 May 14;247(18):2543-6.
Zotero 插件